# Cancer Biology and Therapeutics (CBT)

> **NIH NIH P30** · DARTMOUTH COLLEGE · 2020 · $58,191

## Abstract

Project Summary/Abstract: Cancer Biology and Therapeutics
The Cancer Biology and Therapeutics (CBT) Program brings together 37 faculty, representing 12 departments
at Dartmouth’s Geisel School of Medicine (Geisel), its Guarini School of Graduate and Advanced Studies, and
the Dartmouth-Hitchcock Medical Center (DH), with research interests relevant to three central CBT Program
themes: 1) Cancer cell signaling and metabolism, 2) Cell cycle biology and genome stability, and 3) Chromatin
biology and oncogenic transcription. The shared goals of the CBT Program are to: i) advance the
understanding of the basic mechanisms that underlie cancer initiation, progression, and metastasis to support
prevention, diagnosis and treatment of cancer; ii) identify and validate new pathways and molecular targets for
effective therapeutic intervention; iii) facilitate bi-directional translation to develop and improve novel
therapeutic and diagnostic strategies. Peer-reviewed cancer-related research direct cost support currently
totals $7.0M, with NCI funding representing 25% ($1.8M) and total direct costs summing to $7.9M. Twenty (20)
CBT Program Members currently have a total of 28 CCSG-defined R01-equivalent awards. Using the same
definition of cancer-related direct costs in 2014 (i.e., excluding all indirects as well as training and
administrative direct costs), peer-reviewed cancer-related research direct costs ($7.0M) are up 14% compared
to the combination of Cancer Mechanisms and Molecular Therapeutics in 2014 ($6.1M). Since 2015, the CBT
Program has 446 cancer-related publications, 22% (98) intra-programmatic, 24% (109) inter-programmatic,
52% (232) with investigators from other institutions, and 24% (97) in high impact journals (i.e., impact factor
>8). Compared to the combination of Cancer Mechanisms and Molecular Therapeutics in 2014, intra-
programmatic publications have increased, to 22% from 15%, along with inter-programmatic (to 24% from
21%) and high impact (to 24% from 22%) in the current reporting period. The CBT Program will continue to
pursue the proposed Specific Aims through building and strengthening multidisciplinary collaborations between
basic, translational, and clinical researchers, mentorship of junior faculty members to academic independence,
and promotion of partnerships of clinicians and laboratory scientists to drive the development of investigator-
initiated clinical studies.

## Key facts

- **NIH application ID:** 9855313
- **Project number:** 2P30CA023108-41
- **Recipient organization:** DARTMOUTH COLLEGE
- **Principal Investigator:** Scott A. Gerber
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $58,191
- **Award type:** 2
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9855313

## Citation

> US National Institutes of Health, RePORTER application 9855313, Cancer Biology and Therapeutics (CBT) (2P30CA023108-41). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9855313. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*